These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 1606292)
1. Comparison of fibrin-mediated stimulation of plasminogen activation by tissue-type plasminogen activator (t-PA) and fibrin-dependent enhancement of amidolytic activity of t-PA. Fischer BE Blood Coagul Fibrinolysis; 1992 Apr; 3(2):197-204. PubMed ID: 1606292 [TBL] [Abstract][Full Text] [Related]
2. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA. Lijnen HR; Van Hoef B; De Cock F; Collen D Thromb Haemost; 1990 Aug; 64(1):61-8. PubMed ID: 2148848 [TBL] [Abstract][Full Text] [Related]
4. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants. de Vries C; Veerman H; Nesheim ME; Pannekoek H Thromb Haemost; 1991 Mar; 65(3):280-5. PubMed ID: 1904654 [TBL] [Abstract][Full Text] [Related]
5. [Mechanisms of activation of tissue-type plasminogen activator]. Fischer B Arzneimittelforschung; 1990 May; 40(5):625-32. PubMed ID: 2116805 [TBL] [Abstract][Full Text] [Related]
6. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. Collen D J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of fibrinogen and fibrin products and isolated peptide chains on the fibrin-mediated stimulation of plasminogen activation by tissue-type plasminogen activator, and on the fibrin-dependent enhancement of the amidolytic activity of one-chain tissue-type plasminogen activator. Fischer B Biol Chem Hoppe Seyler; 1990 Nov; 371(11):1067-75. PubMed ID: 2128181 [TBL] [Abstract][Full Text] [Related]
10. Characterization of human tissue-type plasminogen activator with monoclonal antibodies: mapping of epitopes and binding sites for fibrin and lysine. Zacharias U; Fischer B; Noll F; Will H Thromb Haemost; 1992 Jan; 67(1):88-94. PubMed ID: 1377416 [TBL] [Abstract][Full Text] [Related]
11. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line. Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244 [TBL] [Abstract][Full Text] [Related]
12. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA). Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847 [TBL] [Abstract][Full Text] [Related]
13. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. Liu JN; Gurewich V J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471 [TBL] [Abstract][Full Text] [Related]
14. The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin. Grailhe P; Boyer-Neumann C; Haverkate F; Grimbergen J; Larrieu MJ; Anglés-Cano E Blood Coagul Fibrinolysis; 1993 Oct; 4(5):679-87. PubMed ID: 8292717 [TBL] [Abstract][Full Text] [Related]
15. Structure and function of human tissue-type plasminogen activator (t-PA). van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031 [TBL] [Abstract][Full Text] [Related]
16. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727 [TBL] [Abstract][Full Text] [Related]
17. Single-chain and two-chain tissue-type plasminogen activator (t-PA) bind differently to cultured human endothelial cells. Aerts RJ; Gillis K; Pannekoek H Thromb Haemost; 1989 Sep; 62(2):699-703. PubMed ID: 2530645 [TBL] [Abstract][Full Text] [Related]
18. Mechanism of potentiation of tissue-type plasminogen activator. Lazos SA; Wong SS Biochem Mol Biol Int; 1995 Dec; 37(6):1071-77. PubMed ID: 8747537 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of fibrin binding on the biochemical properties of single-chain tissue-type plasminogen activator (t-PA) and single-chain chimeric plasminogen activator (t-PA/scu-PA). Fischer BE Blood Coagul Fibrinolysis; 1992 Feb; 3(1):39-46. PubMed ID: 1320415 [TBL] [Abstract][Full Text] [Related]
20. Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen. Grailhe P; Nieuwenhuizen W; Anglés-Cano E Eur J Biochem; 1994 Feb; 219(3):961-7. PubMed ID: 8112348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]